Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Going below $10 soon!
Not surprised! Too much downside!
Going to $5 for sure!!! ROFLMAO
I received letter from Boeing co about Boeing offering teladoc medical services to employees .
This will be incredible for Tdoc
I do not go to doc offices not to get sick , it works , the worse place to be at flu season is docs office
Telehealth is a good solution that TDOC is ahead of everyone. AMZN had to leave the space also
I think TDOC is the AMZN of healthcare. It could bottom in the teens with a 95% decline from the all time high and then climb to $500 and higher.
"Investors who stuck with Amazon through the roller coaster ride of the dot-com bubble around 2000 would have been handsomely rewarded for their patience. The stock soared from a split-adjusted IPO price of $1.50 per share to $106.69 per share on Dec. 10, 1999. From there, it proceeded to fall 96% until it bottomed on Sept. 28, 2001, at $5.97 per share."
Cathie Wood is taking her ship down and continually buying TDOC. If she is forced to start liquidating your gonna see TDOC sub $20 without a doubt. ARKK is teetering on Collapse and she is going to have to make some drastic decisions in the coming months as the Outflows are approaching 1 billion in her fund.
TDOC needs a new CEO. This one is incompetent, if not criminal.
Indeed! This garbage will first go below $25 soon!
Probably 15.00 here before 55
Livingo wasn’t worth $18.5 billion to begin with!
I have not. Up until today I haven't even looked at TDOC. I love a 'kicked around and trodden over' stock. It's what draws me to them. Then I spend a little time checking them out -so thats where I am right now.
Immediately, I wanted to know why the gap down on earnings.
Of course I found this...Which ties into your comment about Livongo. (Thank you, BTW)
-----------------------------------------------------------------------------------------------------
Teladoc stock plunges more than 30% after earnings outlook slashed, massive impairment charge
By Emily Bary
https://www.marketwatch.com/story/teladoc-stock-plunges-more-than-30-after-earnings-outlook-slashed-massive-impairment-charge-11651094890?siteid=yhoof2
(They weren't kidding when they said MASSIVE)
Shares head toward lowest levels in more than four years as online-medicine company wipes away more than $6.5 billion in goodwill
Telehealth company Teladoc lowered its revenue and earnings forecasts for the full year.
Shares of Teladoc Health Inc. were slammed in after-hours trading Wednesday, after the telemedicine company took an impairment charge of more than $6.5 billion and slashed its full-year outlook.
Teladoc TDOC, -4.16% executives now expect $2.4 billion to $2.5 billion in revenue for the full year, along with $240 million to $265 million in adjusted earnings before interest, taxes, depreciation, and amortization (Ebitda). Their prior forecast called for $2.55 billion to $2.65 billion in revenue and $330 million to $355 million in adjusted Ebitda.
Shares were off nearly 37% in after-hours trading, falling lower than $38 after closing with a 3.1% decline at $55.99. Shares haven’t traded for lower than $38 in a regular session since March 2018.
Teladoc’s new forecast reflects trends that executives are seeing in the market for direct-to-consumer mental-health and chronic-condition services, such as higher advertising costs in the mental-health market that are causing lower-than-anticipated yields on its marketing spending. It also cited an “elongated sales cycle as employers and health plans evaluate their long-term strategies” in the chronic-condition market.
“Despite the revision to our 2022 outlook, we are confident in our strategy, along with our breadth and depth of capabilities,” Chief Executive Jason Gorevic said in a release.
Gorevic shared on Teladoc’s earnings call that about three-quarters of the cut to the revenue outlook was related to the company’s BetterHelp online-counseling product, while the rest reflected new top-line expectations for the chronic-care business.
For the first quarter, Teladoc generated a net loss of $6.67 billion, or $41.58 a share, whereas it recorded a loss of $200 million, or $1.31 a share, in the year-prior period. Teladoc’s loss in the most recent quarter largely reflected a $6.6 billion impairment charge related to goodwill.
Teladoc executives did not disclose much about the goodwill impairment charge in Wednesday’s news release, but roughly $12.8 billion of the $14.5 billion in goodwill on Teladoc’s books stemmed from the $18.5 billion acquisition of Livongo in 2020, according to the company’s filings with the Securities and Exchange Commission.
“The goodwill impairment was triggered by the sustained decline in Teladoc Health share price with a valuation and size of the impairment charge driven by a combination of recent market-based factors such as an increased discount rate and the decreased market multiples for a relevant peer group of high-growth digital health-care companies, as well as updates to our forecasted cash flows consistent with the revised guidance disclosed today,” Chief Financial Officer Mala Murthy said in the most substantive statement executives gave about the $6.6 billion charge during a conference call Wednesday afternoon.
The company’s revenue rose to $565.4 million from $453.7 million, while analysts tracked by FactSet had been anticipating $569 million.
For the second quarter, Teladoc projects adjusted Ebitda of $39 million to $49 million on revenue of $580 million to $600 million, while the FactSet consensus is for $71 million in adjusted Ebitda and $615 million in revenue.
Teladoc shares had already declined 39% so far this year and more than 70% in the past 12 months, as the S&P 500 index SPX, -1.63% declined 12.4% and 0.3% respectively.
Have you seen their financials after the Livongo acquisition? They’re TOAST!!!
Wow. Now that's a stretch. Why?
TDOC looking very good to go bankrupt instead!
Do you think TDOC could buy out Babylon holdings ? BBLN
Needs to get north of 50 again
Up we go, 1984…….
Let’s keep it going, TDOC !!
Made money on way down now time to play bounce
I’m in…….way oversold, imho.
$$ TDOC $$
better healthcare companies than Teladoc out there just have to look
what exactly , geez
Overvalued POS crashed as expected! $25 coming!!!
You called it!
TDOC could buy AMWL
Will see $100 quickly I would assume. Mega fear lately in the market. Easy to overlook value
This is selling at the price we paid for the other company. Without TDOC business included. This is like Stealing
Down 70%. What a BUY
$TDOC Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Nov. 17, 2021: $TDOC $VRAR $ZSAN $RDW $SNDL
Watch out TDOC guess who’s going World Wide ... that’s right HLYK yep Global $$$$$
Teladoc Health: The Recent Crash Was to Be Expected
Despite seeing initial success from the Livongo acquisition, the telehealth provider's losses are widening
Ishan Majumdar
May 03, 2021
Teladoc Health (TDOC, Financial) is a virtual healthcare company that offers a variety of care services, including primary care, mental health, chronic conditions, acute care and more.
The company has caught the eye of many contrarian investors after the recent stock price crash, which was driven largely by the expectation of its pandemic-linked tailwinds disappearing.
With the Livongo (LVGO, Financial) acquisition, the company is making significant investments to integrate and enhance its technology platform and is expected to capitalize on its robust data and behavioral science capabilities across the entire organization. Moreover, the whole-person care strategy of Teladoc that addresses the full spectrum of consumer health needs rather than just one particular disease is a major green flag.
The recent price crash was to be expected given that the pandemic attracted flocks of speculators who never planned to invest for the long-term. However, now that the price has fallen to a more reasonable level, could Teladoc offer returns to investors?
Recent financial performance
Teladoc has witnessed excellent top-line growth over the past year, driven by access fee revenues and visit fee revenues, but its losses have not gone down, which is also one of the reasons for the disappointment of shareholders.
The company reported revenue of $453.68 million for the first quarter of 2021, which was a staggering 150.93% improvement as compared to the $180.80 million reported in the corresponding quarter of the previous year. Apart from the Livongo acquisition, revenues were also driven by strong enrollments in chronic care programs. Teladoc managed to beat the analyst consensus estimate of $451.91 million.
The company's revenues translated into a gross margin of 67.83% and an operating margin of -17.27%, which was lower than that in the same quarter of 2020.
Teladoc reported a net loss of $199.65 million and an adjusted loss per share of $1.31, which was below the average Wall Street expectation of a loss per share of 54 cents. The company burned $18.03 million during the quarter in the form of operating cash losses, and this cash loss was again higher than that in the corresponding quarter of 2020.
Overall, the company has not been performing too well on the financial front and seems to be only increasing its losses as it grows.
The Livongo upside
In October 2020, Teladoc went ahead and acquired digital diabetes service provider Livongo for a consideration of $18.5 billion with a vision to create an all-inclusive virtual healthcare model. The acquisition allows for Teladoc's cross-selling opportunities given the lack of patient overlap with Livongo, thereby partially offsetting pressures from emerging competitors like Amazon Care (AMZN, Financial) and Cigna's (CI, Financial) acquisition of MDLive.
It is worth highlighting that the company's access fee revenue for the first quarter increased 183% year over year to $388 million and is primarily due to the acquisition of Livongo and InTouch Health, both generating the majority of their revenue from subscription access fees.
Moreover, the management stated that, of the 48 cents of sequential increase in PMPM (Per Member Per Month), roughly half was driven by the contribution of an extra month of Livongo revenue in the first quarter. Notably, membership in the Livongo chronic care suite of products grew 66% over the prior year with Teladoc adding 62,000 new chronic care members in the quarter. The company has partially integrated Livongo into the Teladoc app, enabling users to register for Livongo's care management programs for diabetes and hypertension within the same ecosystem.
To sum up, the whole chronic care management offerings from Livongo come as a valuable addition to Teladoc's portfolio after its success in mental health services through the BetterHelp acquisition.
Other key developments
The company has been expanding its offerings for existing clients, as well as adding new clients. Most recently, Teladoc signed an agreement to expand its relationship with a regional Blue Cross Blue Shield plan on the East Coast with a view to offering comprehensive whole-person virtual care solutions to its members.
The company also plans to provide access to its members to the extensive suite of products, including virtual care solutions and a full suite of digital chronic care solutions across diabetes, hypertension, diabetes prevention and mental health. In addition, Teladoc's Primary360 offering continues to gain significant traction from health plans, employers and also hospitals and health systems, thereby delivering encouraging results.
Internationally, the company partnered with Generali Hong Kong, a leading insurance carrier, to offer virtual care solutions to its members across Asia. In Australia, Teladoc announced its collaboration with MetLife (MET, Financial) to offer access to a customized platform across its comprehensive virtual care service to MetLife's members in the region.
Overall, there appear to be a number of good opportunities that could drive revenue growth in the long term.
Valuation
As we can see from the chart above, the stock price of Teladoc took a massive beating from its February 2021 highs after yet another wider-than-expected loss and weak guidance for paid U.S. memberships. Investors are worried about the continued losses and the inability of the management to show any kind of positive bottom-line as of yet.
Despite the crash, the company is still trading at a very high enterprise-value-to-revenue multiple of close to 25, which is above the healthcare services industry average. Thus, I believe Teladoc is a risky investment at current levels given its losses.
On the other hand, the company has a huge growth opportunity in telehealth after the acquisitions of Livongo and InTouch Health. In my opinion, investors should keep the company on their watch list until we see some positive news or some kind of strength in its financial performance.
Followers
|
29
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
272
|
Created
|
08/11/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |